Trials Sponsors Conditions Drugs Pricing

Conditions

Type 2 Diabetes

Outcome Measures

Primary Outcomes (1)

6-month clinical glycemic control rate
6-month clinical glycemic control rate (clinical control defined as HbA1c \< 7.0%)
6 months

Secondary Outcomes (9)

Change in HbA1c from baseline
12 months
Change of β cell function
12 months
Change of insulin sensitivity
12 months
Change of lipid profiles
12 months
Change of body weight
12 months
+4 more secondary outcomes

Interventions

Metformin Hydrochloride and Empagliflozin tables (Fixed-Dose Combination)Drug

First-time treatment with Metformin Hydrochloride and Empagliflozin Tablets (metformin 500mg and empagliflozin 5mg per table) for at least 6 months

Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.

Registry intervention entries

These entries preserve how the registry describes the intervention. Their treatment roles are shown separately from molecular identities.

Grouped treatment entry
Metformin Hydrochloride and Empagliflozin tables (Fixed-Dose Combination)
The registry names several treatments. This does not confirm that participants received them together or that they form a single product.
View registry record

Eligibility Criteria

Age18 Years+

Sexall

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

Sampling MethodProbability Sample

Study Population

Outpatient and inpatient patients

You may qualify if:

Age ≥ 18 years, gender unrestricted;

Sponsors & Collaborators

The Second People's Hospital of Changshu
Type not reportedcollaborator
Liaoning Health Industry Group Fushun Mining General Hospital
Type not reportedcollaborator

Study Sites (1)

Endocrinology Department, The First Affiliated Hospital of Sun Yat-sen University

Guangzhou, Guangdong, China

MeSH Terms

Conditions

Diabetes Mellitus, Type 2

Interventions

Metformin

Condition Hierarchy (Ancestors)

Diabetes MellitusGlucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesEndocrine System Diseases

Intervention Hierarchy (Ancestors)

BiguanidesGuanidinesAmidinesOrganic Chemicals

Study Design

Study Type: observational
Observational Model: COHORT
Time Perspective: PROSPECTIVE
Target Duration: 1 Year
Sponsor Type: OTHER
Responsible Party: PRINCIPAL INVESTIGATOR
PI Title: the director of the endocrinology department of the First Affiliated Hospital of Sun Yat-sen University

Study Record Dates

First Submitted

January 14, 2025

First Posted

June 4, 2025

Study Start

August 2, 2023

Actual (reported)

Primary Completion

December 31, 2025

Metformin Hydrochloride and Empagliflozin Tablets in the Treatment of Type 2 Diabetes

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (9)

Interventions

Registry intervention entries

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Conditions

Interventions

Condition Hierarchy (Ancestors)

Intervention Hierarchy (Ancestors)

Study Design

Study Record Dates

You may not qualify if:

Source record

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (9)

Interventions

Registry intervention entries

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Conditions

Interventions

Condition Hierarchy (Ancestors)

Intervention Hierarchy (Ancestors)

Study Design

Study Record Dates

You may not qualify if:

Source record

Locations